Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis
Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis
复制标题
DOI：
10.1159/000381948
复制
发表时间：
2015-01-01
期刊：
影响因子：
3.4
通讯作者：
Xu, Bo
中科院分区：
文献类型：
--
作者：
Huang, Xia;Xu, Bo
目的：通过网络荟萃分析，我们旨在比较他克莫司和吡美莫司作为儿童特应性皮炎（AD）治疗方案的有效性和安全性。方法：对 AD 儿科患者使用他克莫司或吡美莫司进行的改良 Jadad 评分 >3 的随机对照研究进行了研究。结果：从 163 篇文章中，选出了 19 项研究，总共纳入了 6,413 名儿科患者。汇总分析显示，与赋形剂相比，他克莫司 0.03% 或 0.1% 和吡美莫司 1% 在减少湿疹方面效果更好。他克莫司和吡美莫司在改善湿疹严重程度方面没有发现任何意义。与他克莫司和吡美莫司组相比，媒介物组中有更多患者倾向于退出。他克莫司组和吡美莫司组的不良事件总数和停药率之间没有显着差异。结论：吡美莫司治疗儿童 AD 的疗效和安全性与他克莫司相似，但均优于溶媒。 (C) 2015 S. Karger AG，巴塞尔
Objective: Using a network meta-analysis, we aimed to compare the efficacy and safety of tacrolimus and pimecrolimus as treatment options for children with atopic dermatitis (AD). Methods: Randomized controlled studies with a modified Jadad score >3 using tacrolimus or pimecrolimus in pediatric patients with AD were studied. Results: Out of 163 articles, 19 studies enrolling a total of 6,413 pediatric patients were selected. Pooled analysis revealed that tacrolimus 0.03% or 0.1% and pimecrolimus 1% were better at reducing eczema compared with vehicles. No significance was found between tacrolimus and pimecrolimus in improving the severity of eczema. More patients tended to withdraw in the vehicle groups compared to the tacrolimus and pimecrolimus groups. No significant difference existed between total adverse events and withdrawals in the tacrolimus and pimecrolimus groups. Conclusions: Pimecrolimus was similar to tacrolimus in both efficacy and safety for AD in children, but both were better than vehicles. (C) 2015 S. Karger AG, Basel